144 related articles for article (PubMed ID: 1737381)
21. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
22. Immunological reactivity of mucinous and serous ovarian adenocarcinomas.
Harłozińska-Szmyrka A; Slesak B; Richter R; Rabczyński J; Cisło M
Cancer Detect Prev; 1986; 9(3-4):347-58. PubMed ID: 3017557
[TBL] [Abstract][Full Text] [Related]
23. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
25. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
26. [Tumor markers in the monitoring of ovarian cancer].
Xu SX
Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
[TBL] [Abstract][Full Text] [Related]
27. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
Liu LY
Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
[TBL] [Abstract][Full Text] [Related]
28. [Diagnosis of ovarian tumor by measuring tumor markers].
Fukatsu T; Nakashima N; Takeuchi J
Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
[TBL] [Abstract][Full Text] [Related]
29. [Clinical significance of serum sialyl Tn antigen in patients with gynecological cancer. STN Study Group].
Noda K; Shiota M; Tanizawa O; Inoue M; Tenjin Y; Sugishita T; Yakushiji M; Miyoshi T; Nozawa S; Sakuma T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1287-96. PubMed ID: 2069400
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
[TBL] [Abstract][Full Text] [Related]
31. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
32. Significance of tumor marker determinations in the primary therapy of ovarian cancer.
Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2949-51. PubMed ID: 9329572
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
34. [Heterogeneity of the CA125 antigen that coexpresses sialyl Tn and CA19-9 antigens].
Kobayashi H; Ohi H; Shinohara H; Terao T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Sep; 45(9):980-6. PubMed ID: 8371024
[TBL] [Abstract][Full Text] [Related]
35. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
Chen DX; Li FQ
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
Kuzuya K; Nozaki M; Chihara T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
[TBL] [Abstract][Full Text] [Related]
38. [An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels].
Usui N; Suzuki M; Takada M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jun; 44(6):703-9. PubMed ID: 1506732
[TBL] [Abstract][Full Text] [Related]
39. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
40. Peritoneal fluid lactate dehydrogenase in ovarian cancer.
Schneider D; Halperin R; Langer R; Bukovsky I; Herman A
Gynecol Oncol; 1997 Sep; 66(3):399-404. PubMed ID: 9299252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
